BD Biosciences has announced that William Rhodes has been promoted to the position of president, cell analysis.
BD Biosciences said that it has recently restructured its cell analysis business unit, and that as a result, Rhodes has taken on additional responsibilities including the sales and technical service organizations. Rhodes, who previously served as vice president and general manager for cell analysis, will continue to report to Vince Forlenza, president of BD Biosciences. Rhodes has held several positions at BD since joining the company more than seven years ago, including vice president and general manager of immunocytometry systems, vice president of business development and strategic investments, and general manager of BD Ventures.
Sigma-Aldrich this week named Carl Turza as chief information officer, effective May 1.
Turza will lead the company's information technology and internet functions. He has previously worked for WW Grainger and AlliedSignal Aerospace, among other organizations, Sigma said. He holds an MBA from the University of Illinois.
Invitrogen has named former NIH stem cell section chief Mahendra Rao vice president of research of its Stem Cells and Regenerative Medicine business.
Rao has also served as a senior investigator in the laboratory of neuroscience for the NIH's National Institute on Aging. He holds an MD from Bombay University in India and a PhD in developmental neurobiology from the California Institute of Technology.
BD Biosciences' bioimaging systems division this week announced the release of IPLab v4.0 for the Windows operating system.
IPLab is an image-acquisition, -processing, and -analysis software for biological applications. IPLab v4.0 introduces new features such as a multidimensional acquisition feature called 6D Acquire to simplify complex live-cell, time-lapse experiments. This feature provides a step-by-step interface for acquiring multiple wavelength time-lapse images, including Z-stacks, from multiple locations. IPLab v4.0 also has a new autofocus feature, BD Biosciences said.
BD Biosciences acquired the IPLab technology from Scanalytics in July 2005 (see CBA News, 7/18/2005), to enhance the analysis the capabilities of its CARV II microscopy technology and Pathway HT high-content imaging platform.
DiscoveRx this week announced it has expanded its PathHunter line of products with two new cell-based mitotic index assays.
The PathHunter mitotic index assays are ready-to-use cellular assays based on DiscoveRx's EFC biosensor technology, a homogenous assay format with chemiluminescence signal generation. Like other PathHunter assays, the mitotic index assays are engineered biosensor cell lines with separate nuclear and cytoplasmic fragments of ß-galactosidase. Complementation of the fragments occurs during the disassembly of the nuclear membrane at mitosis, enabling assays for screening or pathway profiling, DiscoveRx said.